Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.
In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.
Novartis International AG CH-4002 Basel Switzerland
Through our business, we make an important contribution to society: We discover and develop innovative healthcare products, targeting unmet medical needs. Novartis medicines reach nearly 1 billion people each year.
In 2016, our access-to-healthcare programs reached nearly 52 million patients with Novartis products and nearly 17 million with people with health education, infrastructure development and other programs.
Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products.
Novartis on FORTUNE's list of the World's Most Admired Companies Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.
Novartis ranks third in 2016 Access to Medicine Index Novartis ranked third in the 2016 Access to Medicine Index, up from 4th place in 2014. We topped the industry in access-to-medicine management and capacity building, and our integrated access strategy addressing all income segments stood out as best practice.
Two Novartis products receive 2016 Prix Galien Foundation Awards Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate).
Novartis included in Dow Jones Sustainability World Index Novartis is proud to again be included in the Dow Jones Sustainability World Index, and to be recognized for its efforts in sustainability. The Index is an annual evaluation of the sustainability practices of 3400 of the world’s largest listed companies. Companies are listed in the annual ranking if they are best in class within their industry for sustainability.